To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva

← catalyst calendar

NCT05090891 · readout in 345 d

Sponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.

Phase

Phase 2

Status

Recruiting

Study type

Interventional

Design

Randomized · Double · Treatment

Enrollment

98estimated

Sites

Countries

Argentina, Australia, Brazil +14

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2022-05-05

actual

When the study began enrolling

Primary completion

2027-07-30

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2033-01-20

estimated

The whole study's end, after follow-up

First posted

2021-10-25

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-05-22

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Fibrodysplasia Ossificans Progressiva (FOP)

Interventions

Drug: INCB000928 — also filed as zilurgisertib
Drug: Placebo

Primary outcome

what the primary-completion date above is the date OF

Double Blind Period: Occurrence of new heterotopic ossification (HO) lesions from baseline

measured Week 24

Publications

PMID 41360500 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed